EODData

MEMBERSHIP REGISTER LOG IN

FRA, 8ZD: ABBISKO CAYMAN DL-00001

28 Jul 2026
LAST:

1.160

CHANGE:
 0.01		OPEN:
1.150		HIGH:
1.160		ASK:
0.000		VOLUME:
0
CHG(%):
0.85		PREV:
1.170		LOW:
1.150		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Jul 261.1501.1601.1501.1600
27 Jul 261.1701.1701.1701.1700
24 Jul 261.1801.1901.1801.1900
23 Jul 261.1801.1801.1801.1800
22 Jul 261.1701.1701.1701.1700
21 Jul 261.1801.1901.1801.1900
20 Jul 261.1601.1701.1601.1700
17 Jul 261.1201.1301.1201.1300
16 Jul 261.2201.2301.2201.2300
15 Jul 261.2401.2501.2401.2500

PROFILE

Name:ABBISKO CAYMAN DL-00001
About:Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; and Irpagratinib (ABSK011), a small molecule inhibitor of FGFR4 for the treatment of advanced hepatocellular carcinoma. In addition, the company develops products in Phase Ib/II trial, such as Fexagratinib (ABSK091) for the treatment of urothelial carcinoma; ABSK061, a small molecule inhibitor targeting FGFR 2/3 to treat solid tumors and achondroplasia; and ABSK043, a PD-L1 inhibitor for the treatment of non-small cells lung cancer (NSCLC). Further, it is developing products in Phase I/Ia trial comprising ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3 to treat solid tumors; ABSK112, an EGFR Exon20ins inhibitor for the treatment of NSCLC; and ABSK051, a small molecule CD73 inhibitor to treat various tumor types, such as lung and pancreatic cancer, as well as IND-stage trial products, including ABSK012, a small molecule FGFR4 inhibitor for treatment of rhabdomyosarcoma, advanced solid tumors, and soft tissue sarcoma; ABK3376, an EGFR inhibitor to treat NSCLC harboring the EGFR-C797S mutation; and ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor for the treatment of solid tumors. Additionally, the company's pre-clinical pipeline products comprise P017, P018, ASBK141, P021, P019, and P020 to treat solid tumors; and P151 for non-oncology indications. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:Building 3, Shanghai, China
Website:https://www.abbisko.com
ISIN:KYG0028A1085

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:119.00 
Price to Sales:1.40 
Price to Book:3.24 
Profit Margin:0.09 
Operating Margin:0.05 
Return on Assets:0.01 
Return on Equity:0.03 
Revenue:78.98M 
EBITDA:140.09M 
Shares:659.75M 
Market Cap:765.31M 

TECHNICAL INDICATORS

MA5:1.171.2%
MA10:1.182.1%
MA20:1.214.0%
MA50:1.114.8%
MA100:1.235.8%
MA200:1.3920.1%
STO9:30.00
STO14:25.00
RSI14:42.86
WPR14:-75.00
MTM14:-0.03
ROC14:-0.03 
ATR:0.03 
Week High:1.192.6%
Week Low:1.150.9%
Month High:1.2911.2%
Month Low:1.1220.1%
Year High:2.1081.0%
Year Low:0.9522.1%
Volatility:8.96